Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenex SE $ARGX Shares Sold by Bamco Inc. NY
03:56am, Saturday, 13'th Dec 2025
Bamco Inc. NY lowered its stake in argenex SE (NASDAQ: ARGX) by 15.3% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 180,733
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Friday, 12'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the
Axa S.A. Boosts Stock Holdings in argenex SE $ARGX
04:36am, Thursday, 11'th Dec 2025
Axa S.A. raised its position in shares of argenex SE (NASDAQ: ARGX) by 5.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commi
argenx: Sights Set On $1,000
11:15am, Wednesday, 26'th Nov 2025
argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net
Artisan Partners Limited Partnership Has $1.30 Billion Stock Position in argenex SE $ARGX
03:56am, Wednesday, 19'th Nov 2025
Artisan Partners Limited Partnership decreased its position in argenex SE (NASDAQ: ARGX) by 15.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Com
Baron Opportunity Fund Q3 2025 Portfolio Update
10:06am, Tuesday, 18'th Nov 2025
This quarter, we re-established a position in Arista Networks, a leading provider of high-performance networking solutions for data centers, cloud providers, and enterprises. We initiated a starter po
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
02:31pm, Sunday, 16'th Nov 2025
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:49pm, Monday, 10'th Nov 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks is more a
Baron International Growth Fund Q3 2025 Contributors And Detractors
05:40am, Thursday, 06'th Nov 2025
Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA Index. Lynas Rare Earths' shares nearly doubled during the quarter as geop
argenex SE $ARGX Shares Acquired by Sumitomo Mitsui Trust Group Inc.
04:11am, Saturday, 01'st Nov 2025
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of argenex SE (NASDAQ: ARGX) by 27.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securitie
argenx SE (ARGX) Q3 2025 Earnings Call Transcript
04:26pm, Thursday, 30'th Oct 2025
argenx SE ( ARGX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - C
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
02:00am, Thursday, 30'th Oct 2025
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of an
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
11:00am, Wednesday, 29'th Oct 2025
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity Final ADAPT SC+ results sho
argenex SE $ARGX Shares Sold by Ethic Inc.
04:08am, Wednesday, 29'th Oct 2025
Ethic Inc. trimmed its holdings in argenex SE (NASDAQ: ARGX) by 14.9% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,003 shares of the company's stock
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
01:27pm, Monday, 27'th Oct 2025
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno
